Clinicians are increasingly asking whether type 2 diabetes medications can be added to insulin regimens for type 1 diabetes patients who still struggle with glucose control.
Metformin as an adjunct to insulin
Metformin works by lowering liver glucose production and improving muscle uptake, which can make the body respond better to the insulin that is already being administered. Studies cited in a recent systematic review showed modest reductions in A1C and body weight when metformin was combined with basal‑bolus insulin.
The drug does raise the chance of gastrointestinal upset, but trials have not reported higher rates of diabetic ketoacidosis or low blood sugar. A typical strategy is to start with a low dose at mealtime and increase gradually to improve tolerance.
When metformin is introduced, insulin requirements often fall by roughly 10%–20%, though the exact adjustment depends on each individual’s glucose profile.
SGLT2 inhibitors and safety concerns
Sodium‑glucose cotransporter‑2 inhibitors—including canagliflozin, empagliflozin and dapagliflozin—cause the kidneys to excrete excess glucose. In people with type 1 diabetes, these agents have been linked to lower insulin doses, reduced A1C, weight loss and lower fasting glucose.
Related: Pharmacy Practices Embrace New Learners with Five Tips
Side effects are dominated by genital infections such as vaginitis and balanitis. More serious is the risk of euglycemic ketoacidosis, especially during illness, surgery or pump failure.
Because the cardiovascular and kidney benefits seen in type 2 diabetes have not been confirmed in type 1 diabetes, clinicians should weigh the potential glucose‑lowering effect against the added safety burden.
GLP‑1 receptor agonists and emerging options
GLP‑1 receptor agonists—semaglutide, dulaglutide and liraglutide—slow gastric emptying, curb glucagon release and often lead to weight loss. Evidence suggests they can also improve insulin sensitivity and cut insulin doses in type 1 diabetes.
These drugs share a higher likelihood of gastrointestinal side effects compared with metformin.
Initial dosing mirrors that used for type 2 diabetes, but clinicians sometimes find benefit at lower levels. Dose adjustments are guided by how well glucose stays within target and how tolerable the side effects are.
Related: New AAD guidelines expand eczema treatment options
Specialists emphasize that none of these agents should replace insulin; they are strictly adjuncts.
In practice, the decision to add any of these medications rests on a balance of potential benefits—lower insulin doses, modest A1C improvement, weight loss—against risks such as ketoacidosis or gastrointestinal discomfort.
For a newcomer, the key point is that insulin resistance can develop in type 1 diabetes, making the disease behave partly like type 2 diabetes. Adding a drug that improves insulin sensitivity or reduces glucose load may help smooth out daily swings without replacing the essential insulin.
Side‑effect profile summary: gastrointestinal upset (metformin, GLP‑1 agonists), genital infections (SGLT2 inhibitors), euglycemic ketoacidosis (SGLT2 inhibitors), possible nausea (GLP‑1 agonists).
Rhonda Roedler, a pharmacist in Calgary, notes that careful patient selection and close monitoring are critical when these off‑label therapies are used, especially in the context of insulin pump failures or acute illness.
